Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Merck & Company (MRK – Research Report) and Protagonist Therapeutics (PTGX – Research Report). Sarepta Therapeutics (SRPT) Needham analyst Gil Blum maintained a Buy rating on Sarepta Therapeutics today and set a price target of $166.00. The company's shares closed last Monday at $91.29. According to TipRanks.com, Blum 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -17.4% and a 19.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Rocket Pharmaceuticals, and Taysha Gene Therapies. Currently, the analyst consensus on Sarepta Therapeutics is a Moderate Buy with an average price target of $117.64, which is a 22.3% upside from current levels. In a report issued on September 27, Leerink Partners also initiated coverage with a Buy rating on the stock. See today’s analyst top recommended stocks >> Merck & Company (MRK) Berenberg Bank analyst Luisa Hector maintained a Hold rating on Merck & Company yesterday and set a price target of $92.00. The company's shares closed last Monday at $79.93. According to TipRanks.com, Hector is a 3-star analyst with an average return of 8.6% and a 87.5% success rate. Hector covers the Healthcare sector, focusing on stocks such as Roche Holding AG, Bristol Myers, and Sanofi. Currently, the analyst consensus on Merck & Company is a Moderate Buy with an average price target of $92.78, which is a 13.7% upside from current levels. In a report issued on October 6, Bank of America Securities also maintained a Hold rating on the stock with a $85.00 price target. Protagonist Therapeutics (PTGX) In a report released today, Joseph Schwartz from Leerink Partners maintained a Buy rating on Protagonist Therapeutics, with a price target of $50.00. The company's shares closed last Monday at $35.36. According to TipRanks.com, Schwartz is a 4-star analyst with an average return of 8.4% and a 44.0% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Ultragenyx Pharmaceutical, and Crinetics Pharmaceuticals. Currently, the analyst consensus on Protagonist Therapeutics is a Strong Buy with an average price target of $53.43, a 56.8% upside from current levels. In a report released yesterday, JMP Securities also maintained a Buy rating on the stock with a $47.00 price target. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on SRPT: Interfor (IFSPF) Received its Third Buy in a Row MTY Food Group (MTYFF) Receives a Hold from Scotiabank Wells Fargo Remains a Buy on American Tower (AMT) Dow Inc (DOW) Received its Third Buy in a Row KKR Announces Succession and Reorganization Plans